Comparing the current results to its competitors, Bausch Health Companies Inc reported Revenue increase in the 1 quarter 2026 by 11.73 % year on year. The revenue growth was below Bausch Health Companies Inc 's competitors' average revenue growth of 12.74 %, achieved in the same quarter.
Bausch Health Companies Inc , slower than the average decrease reported by the company's competitors of -43.3 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -43.3 %
Bausch Health Companies Inc 's Comment on Competition and Industry Peers
The competitive landscape includes the acquisition of DURECT Corporation and the planned separation of the eye health business, which comprises Bausch + Lomb's global Vision Care, Surgical, and Pharmaceuticals businesses. Competitors identified in filings include Bausch + Lomb and DURECT Corporation.
Overall company revenue, increased less, than total company revenues, at 11.73 % and lost market share, to approximately 1.95 %. << More on BHC Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Bausch Health Companies Inc
Renovorx Inc Share Performance
+201.80%
This Year
Renovorx Inc
Profile
Renovorx Inc is a medical technology company specializing in the development of innovative treatments for cardiovascular diseases. Their business model focuses on creating and commercializing minimally invasive therapies for patients suffering from conditions like myocardial infarction and heart failure. By leveraging cutting-edge medical devices and procedures, Renovorx aims to provide effective and efficient treatments that can significantly improve patient outcomes and quality of life.
Royalty Pharma Plc operates as a pharmaceutical investment company, focusing on acquiring and managing royalty interests in approved drugs. Their business model primarily revolves around purchasing existing royalty streams in exchange for upfront payments, allowing them to generate ongoing cash flows from the sales of these drugs. They aim to provide liquidity to stakeholders, such as biotech and pharmaceutical companies, by offering a financial alternative to traditional financing options.
Sage Therapeutics Inc's business model primarily revolves around researching, developing, and commercializing innovative therapies for various central nervous system disorders. The company focuses on discovering novel molecules and applying them to create targeted treatments that address the unmet medical needs of patients. By harnessing scientific advancements and strategic collaborations, Sage aims to deliver transformative therapies for individuals suffering from conditions such as depression, postpartum depression, and other mood disorders.
Scpharmaceuticals Inc's business model involves the development and commercialization of innovative pharmaceutical products. They aim to create and bring to market novel therapies that improve patient access, safety, and convenience. Their approach focuses on leveraging their proprietary technology to develop and deliver drugs in a unique and effective manner.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Sources:
Bausch Health Companies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bausch Health Companies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
